You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

 

Online download statistics by month:

Online download statistics by month: March 2024 to January 2026

AbstractFullPdf
Mar 2024923929414
Apr 2024582584264
May 2024394396192
Jun 2024197202154
Jul 2024399399133
Aug 2024210208151
Sep 2024242242194
Oct 2024248252156
Nov 2024248249155
Dec 2024276282175
Jan 2025279283195
Feb 2025320320246
Mar 2025251251232
Apr 2025286286185
May 2025266271219
Jun 2025167169124
Jul 2025110
Aug 2025220
Jan 2026110
Total529253273189